Wikipedia -WSS

Wikipedia

author：focus 2025-10-03 00:38:26 - browse：39

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

Alnylam Pharmaceuticals said Thursday that sales of its treatments for rare diseases grew 43% in the second quarter compared to the year-ago period, as the biotech prepares for a key meeting with the Food and Drug Administration in September.

Net product sales in the quarter were $306 million, led by Amvuttra, the company’s RNAi treatment for hereditary ATTR, with sales of $132 million, exceeding Wall Street forecasts. Sales of Onpattro, its older medicine for hereditary ATTR, were $91 million, slightly less than expectations.

The FDA has scheduled a meeting of outside experts on Sept. 13 to discuss the company’s application to expand the indication for Onpattro to include ATTR-CM, a related condition that affects the heart. The FDA decision is due by Oct. 8. An expansion would open a much larger market for the drug than its current approval, which largely targets nerve-related damage.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

WSS

In the gardens at Boston Children's Hospital, families find sanctuary

Steward Health Care has deal to sell doctor network to UnitedHealth

Merck drug for rare lung condition set for approval in U.S.

What to watch for from Zogenix and Amicus clinical trials

Former reverend arrested for allegedly killing 8

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

leisure time

Wikipedia

focus

Trump demands the U.S. pay no more for drugs than other countries … again

There's no autism epidemic. It's an autism diagnosis epidemic

In age of alternative facts, a scholarly course on calling out crap

Merck drug for rare lung condition set for approval in U.S.

Sports medicine is finally prioritizing gender equality

Supreme Court mifepristone arguments center on docs' right to sue

BioMarin wins approval for gene therapy to treat hemophilia A

Senate panel puts off hardest PBM reforms for another day

Novavax promises a turnaround & Lilly roils the obesity market

The haunting brain science of long Covid

focus

Steward Health Care has deal to sell doctor network to UnitedHealth

What to watch for from Zogenix and Amicus clinical trials

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

The haunting brain science of long Covid

Readout Newsletter: Merck, Vertex, and Viking updates

Democrats decry new health bill for going easy on private equity

explore

hotspot

hotspot

focus